Search

Displaying results 2441 - 2450 of 7600 in total
  1. Drug

    Pramipexole

    go.drugbank.com/drugs/DB00413
    ApprovedInvestigational

    In addition to the above FDA approval for Parkinson's Disease, pramipexole was also approved by the FDA in 2006 for the treatment of Restless Legs Syndrome (RLS) [A176873].

  2. Drug

    Pimethixene

    go.drugbank.com/drugs/DB13292
    Approved

    Pimethixene is approved for use in Brazil and is marketed under the trade name Muricalm. It is an anticholinergic used in the treatment of bronchitis.

    Categories: Antihistamines for Systemic Use
  3. Drug

    Motixafortide

    go.drugbank.com/drugs/DB14939
    ApprovedInvestigational

    [L48141] It has also been investigated alongside [pembrolizumab] for the treatment of pancreatic cancer.[A261481] … [A261476] Motixafortide was approved by the FDA in September 2023, in combination with filgrastim, for use in stem cell mobilization prior to autologous stem cell transplant in patients with multiple

  4. Drug

    Methyprylon

    go.drugbank.com/drugs/DB01107
    ApprovedIllicitWithdrawn

    Methyprylon is a sedative of the piperidinedione derivative family that was previously used for the treatment of insomnia.

  5. Drug

    Acoramidis

    go.drugbank.com/drugs/DB17999
    ApprovedInvestigational

    Acoramidis is a small molecule stabilizer of transthyretin (TTR) for use in patients with TTR amyloidosis. … [A264768] Although they share a mechanism of action, acoramidis is more selective for TTR and is a more potent stabilizer when compared to tafamidis.

  6. Drug

    Etilamfetamine

    go.drugbank.com/drugs/DB13285
    Experimental

    However, being on the controlled drug and substance act does not necessitate that the drug is approved for sale on the market.

  7. Drug

    Carbimazole

    go.drugbank.com/drugs/DB00389
    Approved

    Carbimazole is metabolized to methimazole, which is responsible for the antithyroid activity.

  8. Drug

    Daraxonrasib

    go.drugbank.com/drugs/DB22308
    ApprovedInvestigational

    not candidates for multiagent systemic therapy. … [L64039,L64040] The FDA approved daraxonrasib on August 26, 2026 for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are

  9. Drug

    Desipramine

    go.drugbank.com/drugs/DB01151
    Approved

    See toxicity section below for a complete listing of side effects. … TCAs also block histamine-H<sub>1</sub> receptors, &alpha;<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred

    Categories: Antidepressive Agents Indicated for Depression
  10. Drug

    Aficamten

    go.drugbank.com/drugs/DB18490
    ApprovedInvestigational

    [L54788] Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and